Related references
Note: Only part of the references are listed.Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double-Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin-Structure Infection
G. Ralph Corey et al.
CLINICAL INFECTIOUS DISEASES (2010)
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Helen W. Boucher et al.
CLINICAL INFECTIOUS DISEASES (2009)
Epidemiology of meticillin-resistant Staphylococcus aureus (MRSA) in Latin America
Manuel Guzman-Blanco et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology
Fred C. Tenover et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Waves of resistance: Staphylococcus aureus in the antibiotic era
Henry F. Chambers et al.
NATURE REVIEWS MICROBIOLOGY (2009)
Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia
Alex Soriano et al.
CLINICAL INFECTIOUS DISEASES (2008)
Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains?
Kyle J. Popovich et al.
CLINICAL INFECTIOUS DISEASES (2008)
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms
Martin E. Stryjewski et al.
CLINICAL INFECTIOUS DISEASES (2008)
Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria
Gary J. Noel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Invasive methicillin-resistant Staphylococcus aureus infections in the United States
R. Monina Klevens et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure, infections
George H. Talbot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis, model
Cedric Jacqueline et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Methicillin-resistant S-aureus infections among patients in the emergency department
Gregory J. Moran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Methicillin-resistant Staphylococcus aureus, western Australia
L Dailey et al.
EMERGING INFECTIOUS DISEASES (2005)
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam
EJ Ellis-Grosse et al.
CLINICAL INFECTIOUS DISEASES (2005)
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains
HS Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Methicillin-resistant Staphylococcus aureus:: An evolutionary, epidemiologic, and therapeutic odyssey
S Deresinski
CLINICAL INFECTIOUS DISEASES (2005)
TAK-599, a novel N-phosphono type prodrug of Anti-MRSA cephalosporin T-91825:: Synthesis, physicochemical and pharmacological properties
T Ishikawa et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2003)
Share Paper
